• Dacarbazine Workflows for Cancer Cell Assays

  2026-09-24

  Build more interpretable Dacarbazine assays by accounting for metabolic activation, separating growth inhibition from cell death, and pairing viability measurements with DNA-damage readouts. This practical workflow is designed for melanoma, lymphoma, and sarcoma models—not as a clinical dosing guide.

• KN-62 Workflows for CaMKII Signaling Research

  2026-09-24

  Use KN-62 to test whether CaMKII activity contributes to calcium-dependent secretion, metabolic responses, or cell-cycle phenotypes—without mistaking pathway inhibition for proof of mechanism. This workflow guide also shows how to frame CaMKII experiments alongside recent social-memory findings, while keeping the limits of that connection explicit.

• Cy5 maleimide (non-sulfonated): Workflow Guide

  2026-09-23

  Cy5 maleimide (non-sulfonated), SKU A8139, labels accessible thiols on peptides and proteins with a red-shifted fluorescent tag for imaging and fluorescence assays. It is best suited to samples with available cysteine thiols and tolerance for a small amount of DMSO or ethanol; it is a poor fit when an organic co-solvent cannot be used or thiol selectivity cannot be controlled.

• Docetaxel Workflows for Cancer Research

  2026-09-23

  Build more informative Docetaxel assays by linking microtubule-driven mitotic arrest with apoptosis, viability, and multidrug-resistance readouts. This workflow also shows how Taxotere can support matched parental-versus-resistant models and practical troubleshooting from stock preparation through xenograft study design.

• BPN-19186 in sEH–Nrf2 Osteoclast Assays

  2026-09-22

  BPN-19186 provides a time-controlled chemical approach for connecting soluble epoxide hydrolase activity with lipid mediator balance, Nrf2 signaling, and osteoclast differentiation. This workflow combines biochemical inhibition studies, cellular redox readouts, and orthogonal EET/DHET measurements while emphasizing solubility control and target-engagement validation.

• Cyanin Chloride in a HaCaT Psoriasis Model

  2026-09-22

  A 2024 study evaluated cyanin chloride in chemical antioxidant assays, LPS-stimulated macrophages, and a cytokine-induced HaCaT psoriasis model. Its principal innovation was linking reduced inflammatory signaling, including STAT3 phosphorylation, with recovery of epithelial barrier indicators such as TEER and filaggrin expression.

• Antiarrhythmic Drugs and KCa2 Channel Effects

  2026-09-21

  This study systematically examined whether antiarrhythmic drugs used in atrial fibrillation treatment inhibit human KCa2.2 and KCa2.3 channels. Using automated whole-cell patch clamp, it found meaningful KCa2 inhibition only for dofetilide and propafenone at concentrations substantially above their effective free therapeutic plasma levels, while Vernakalant Hydrochloride did not emerge as a relevant KCa2 inhibitor.

• ML133 HCl: Precision Insights for Kir2.1 Research

  2026-09-21

  A translational perspective on ML133 HCl as a selective potassium channel inhibitor for mechanistic studies of Kir2.1, pulmonary vascular remodeling, and cardiovascular ion channel biology.

• DiR for Longitudinal Membrane Imaging

  2026-09-20

  Discover how DiR (DiIC 18 (7)) can extend nanomedicine studies beyond endpoint biodistribution by enabling longitudinal cell membrane staining, migration analysis, and tissue-level tracking. This practical framework connects near-infrared imaging with the trypsin-responsive acute pancreatitis study while clearly separating membrane localization from therapeutic release.

• Dual Recombinase Tracing Finds No Neo-oogenesis

  2026-09-19

  A dual-recombinase lineage-tracing strategy distinguishes pre-existing germ cells from other ovarian cells across postnatal life and after busulfan-induced injury. The study found no labeled growing oocytes or metaphase II eggs, strengthening the conclusion that mouse ovaries do not generate new oocytes in vivo after birth under the tested conditions.

• KN-62: CaMKII Inhibition for Cell Assays

  2026-09-18

  A scenario-based guide to using KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine (SKU A8180) in calcium-signaling, viability, proliferation, and cytotoxicity workflows. It connects mechanism, solvent handling, assay interpretation, and vendor-selection criteria to improve experimental consistency.

• AMG 487: CXCR3 Antagonist Workflow

  2026-09-18

  AMG 487 enables state-matched dissection of CXCR3 signaling across calcium flux, chemokine migration, macrophage polarization, and autophagy assays. This workflow combines potency-guided assay design with practical controls for solubility, vehicle effects, metabolism, and inflammatory-state interpretation.

• AICAR: Reliable AMPK Activation

  2026-09-17

  A practical, scenario-based guide to using AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), SKU A8184, in cell viability, proliferation, and cytotoxicity workflows. It explains assay confounding, solution preparation, mechanistic controls, data interpretation, and evidence-based product selection.

• G-15 and GPR30: From Estrogen Signals to Pain Circuits

  2026-09-17

  G-15 is a selective G protein-coupled estrogen receptor antagonist that helps translational researchers separate GPR30-mediated signaling from classical estrogen receptor activity. This article connects its calcium and PI3K/Akt pharmacology with emerging evidence that spinal GPR30-positive neurons shape neuropathic pain, while outlining validation strategies, assay controls, and realistic translational boundaries.

• Anti-ROR1 Antibody: Applied Research Workflows

  2026-09-16

  Anti-ROR1 Antibody (Zilovertamab) supports a connected workflow from recombinant ROR1 binding and cell-surface profiling to Wnt5a pathway perturbation. Its strongest differentiation is the ability to pair quantitative ELISA and FACS validation with carefully controlled functional and translational studies.

8072 records 1/539 page Next 12345 下5页 Last page